Results 181 to 190 of about 38,466 (239)

Safety and Feasibility of a "Fast-Track" Monitoring Protocol for Patients Treated With Intravenous Thrombolytic Therapy. [PDF]

Stroke Vasc Interv Neurol
Fukuda KA, Shah K, Kenmuir C, Barnagian D, Nawash B, Desai S, Rocha M, Starr M, Roach E, Henry S, Molyneaux BJ, Jadhav AP.   +11 more
europepmc   +1 more source

Risk of angioedema and thrombolytic therapy among stroke patients: An analysis of data from the FDA Adverse Event Reporting System database. [PDF]

Neurotherapeutics
Xiang H, Ma Y, Luo X, Guo J, Yao M, Liu Y, Deng K, Sun X, Li L.   +8 more
europepmc   +1 more source

Stroke nurse-led intravenous thrombolytic therapy strategy for ischemic stroke based on timeline process: A quality improvement program from China. [PDF]

Int J Nurs Sci
Li B, Zhang Z, Li K, Zhao L, Niu R.
europepmc   +1 more source

Thrombolytic therapy based on lyophilized platelet-derived nanocarriers for ischemic stroke. [PDF]

J Nanobiotechnology
Migliavacca M, Correa-Paz C, Pérez-Mato M, Bielawski PB, Zhang I, Marie P, Hervella P, Rubio M, Maysinger D, Vivien D, Del Pino P, Pelaz B, Polo E, Campos F.   +13 more
europepmc   +1 more source

Support for Thrombolytic Therapy for Acute Stroke Patients on Direct Oral Anticoagulants: Mortality and Bleeding Complications. [PDF]

West J Emerg Med
Koscumb P, Murphy L, Talbott M, Nuti S, Golovko G, Shaltoni H, Jehle D.   +6 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Thrombolytic Therapy

Neurologic Clinics, 1992
Following the successful application of thrombolytic therapy for acute myocardial infarction, investigations have proceeded on several different thrombolytic agents as therapy for ischemic stroke. Early clot lysis has been demonstrated following both intra-arterial and intravenous drug administration.
P F, Lawrence, G R, Goodman
openaire   +4 more sources

Thrombolytic Therapy

New England Journal of Medicine, 1988
Despite their widespread use in patients with acute myocardial infarction, all currently available thrombolytic agents suffer from a number of significant limitations, including resistance to reperfusion, the occurrence of acute coronary reocclusion and bleeding complications.
D, Collen, D C, Stump, H K, Gold
  +7 more sources